Statement: participants of the primary trial will receive the intervention for a total of 30 cycles (210 days)
Primary_evidence: INTERVENTION 1:    Abraxane, Avastin and Gemcitabine   Each treatment cycle is 28 days. Participants will be treated until disease progression:   Gemcitabine: 1500 mg/m2 body surface area (BSA) intravenously (IV) over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by;   Abraxane: 150 mg/m2 IV over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by;   Avastin: 10 mg/kg IV on days 1 and 15 of each cycle.